Services, therapies, nutrients and prices may vary per location
The most common gastrointestinal side effects include: Nausea : Reported in 15-44% of patients (higher rates at Wegovy 2.4 mg), typically most pronounced during dose escalation Diarrhea : Affects approximately 8-30% of users, ranging from mild to moderate severity Vomiting : Occurs in 5-24% of patients (higher rates at Wegovy 2.4 mg), often associated with rapid dose increases Abdominal pain : Experienced by 5-20% of patients, usually described as cramping or discomfort Constipation : Paradoxically affects 3-24% despite the medication's effects on motility Dyspepsia and gastroesophageal reflux : Related to delayed gastric emptying These effects result from semaglutide's pharmacologic action on GLP-1 receptors throughout the gastrointestinal tract
If you have already read "GLP-1 Not Working
Guidelines recommend at least 6 months of intensive structured lifestyle intervention: family-based meal planning, 150+ minutes weekly physical activity, sleep optimization, and mental health support for emotional eating
National Health and Nutrition Examination Survey (NHANES) indicates that approximately 21% of adults, or 43 million individuals, have been diagnosed with hyperuricemia
It emphasizes quality, safety, and established reputation, making it a more trusted option than many emerging alternatives